SWShengjun Wang

Shengjun Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shengjun Wang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Fei Kang

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, China

    1 shared publication
  • Huaxi Xu

    Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, China

    1 shared publication
  • Jing Wang

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi’an, China

    1 shared publication
  • Kui Zhang

    The Pritzker School of Molecular Engineering, the University of Chicago

    1 shared publication
  • Li Yao

    Intensive Care Unit, The First Hospital of Lanzhou University, Lanzhou, China

    1 shared publication
  • Lingjie Jiang

    Intensive Care Unit, The First Hospital of Lanzhou University, Lanzhou, China

    1 shared publication

Latest Publications

  • Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu’s arteritis patients

    by Fei Kang, Qing Han, Xiang Zhou, Zhaohui Zheng, Shengjun Wang, Wenhui Ma, Kui Zhang, Zhiyong Quan, Weidong Yang, Jing Wang, et al.

    Purpose To assess the performance of PET vascular activity score (PETVAS) in comparison with SUVmax, inflammatory biomarkers and ITAS-2010 score in a cohort of TAK patients. Methods Sixty-four PET/CT scans acquired from 54 TAK patients were analyzed. The inflammatory activity was qualitatively determined by physician’s global assessment and quantitatively determined by ITAS-2010 score. SUVmax and PETVAS were acquired by consensus review. Levels of the inflammatory biomarkers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and pentraxin-3 (PTX-3) were measured. Performance of the qualitative diagnoses and the quantitative correlation were, respectively, compared by receiver operating characteristic (ROC) curve and Spearman correlation coefficient. Results The biomarkers (CRP, ESR, PTX-3), PET uptake values (SUVmax, PETVAS), and ITAS-2010 scores were all significantly higher in active patients than in non-active ones. The area under the ROC curve and Youden Index of PETVAS and PTX-3 were higher than those of SUVmax, CRP, ESR, and ITAS-2010. PETVAS and PTX-3 resulted in a higher Spearman correlation coefficient with ITAS-2010 than other criteria, either among all patients or within the active group. Alteration trends of PETVAS and PTX-3 during follow-up showed a tighter correlation with clinical progression/remission assessment than other criteria. Conclusions In TAK evaluation, PETVAS is superior for qualitative and quantitative assessment, compared with the regional SUVmax. Compared to CRP and ESR, inflammatory biomarker PTX-3 shows better qualitative performance and a higher correlation with PETVAS and ITAS-2010. These findings indicate that the use of PETVAS and PTX-3, instead of SUVmax and CRP/ESR, has potential advantages in the clinical evaluation of TAK.


  • Open Access

    Bright light therapy in the treatment of patients with bipolar disorder: A systematic review and meta-analysis

    by Shengjun Wang, Zhigang Zhang, Li Yao, Nannan Ding, Lingjie Jiang, Yuchen Wu

    The treatment of depressive symptoms of bipolar disorder (BD) has received increasing attention. Recently, some studies have shown that bright light therapy (BLT) seems to be useful for BD depression. This meta-analysis is intended to further elucidate the role of BLT in depressive symptoms in patients with BD. Register of Systematic Reviews PROSPERO: CRD 420191 33642.Randomized controlled trials and cohort studies were retrieved in PubMed, Cochrane Library, EMbase, Web of Science, CINHAL, CBM, CNKI, VIP, and Wanfang from their foundation to March 2020, and other sources as supplement was also retrieved. Data were extracted after strict evaluation of literature quality by two researchers, and Meta-analysis was conducted on literatures that met the inclusion criteria. Meta-analysis was performed using Revman 5.3 software. In total, 12 studies including 847 patients with BD depression were included in our meta-analysis. A meta-analysis found significant differences between BLT and placebo for the following outcomes: (1) depression severity before and after BLT [SMD = -0.43, 95% CI (-0.73,-0.13), P2 = 85%, SMD = -1.88, 95% CI (-2.04, -1.71),P2 = 71%, SMD = -2.1,95% CI(-2.24, -1.96), P2 = 0%, SMD = -0.56, 95% CI (-0.92, -0.19), P2 = 97%, SMD = -1.74, 95% CI (-1.99, -1.49), P2 = 0%, SMD = -0.6, 95% CI (-1.06,-0.13), P<0.05]. Limitations of the study include studies only assessed short-term effects, and insufficient duration may underestimate adverse reactions and efficacy. Our results highlight the significant efficiency of BLT in the treatment of bipolar depression. Prospective studies with more rigorous design and consistent follow-up.


  • Clinical and prognostic significance of Arl4c expression in colorectal cancer

    by Xiaobo Chen, Zhaoliang Su, Shengjun Wang, Huaxi Xu

    BACKGROUND: ADP-ribosylation factor (ARF)-like 4c (Arl4c) has been reported to promote tumorigenesis in colorectal and lung cancers and may represent a novel therapeutic target. The aim of this study was to investigate the expression of ADP-ribosylat